Full-Time

Head – Clinical Quality

Posted on 8/28/2024

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor's degree in the Life Sciences with 10+ years in pharmaceutical or biotech drug development. Advanced degree preferred. Minimum 10 years of experience in Clinical QA.
  • Demonstrated experience working with Clinical Trial teams
  • Extensive experience with global clinical trial conduct, knowledge and understanding of ICH E6 GCP Guidelines, FDA Regulations and EU Requirements
  • Previous experience supporting Regulatory Authority Inspections
  • Excellent leadership and interpersonal skills with an ability to effectively work and problem solve within a multidisciplinary team
Responsibilities
  • Participate and proactively provide GXP QA support and guidance in the implementation of GXP compliant procedures and operations to ensure a robust quality management system for the conduct and maintenance of clinical studies
  • Develop and implement process improvements to internal programs as indicated by issue management, audit observations, new regulations, guidance documents, and industry standards. Assist cross-functional teams as necessary with the development, review and implementation of SOPs
  • Lead Inspection Preparation and support Inspection Readiness activities. Drives strategies for Preparation, Support and Follow-up activities for Inspection Readiness
  • Manage the resolution of compliance issues (e.g. CAPAs) identified at clinical vendors and clinical sites and provide assessment of the impact of any deficiencies. Assist teams in the development of CAPA plans and investigations in response to quality issues, audits, and inspections. Lead/chair the clinical portion of Quality Management Review
  • Lead Quality Event Management activities related to the investigation, root cause analysis and development of corrective action/ preventive action plans within Clinical R&D.
  • Collaborate with stakeholders in conducting ongoing risk assessments of clinical study activity to identify priority studies, compliance metrics for tracking, high-risk service providers, and key Clinical QA activities (i.e., protocol review, service provider risk mitigations, inspection readiness)
  • Maintain high level of expertise in global GCP regulations and internal policies and procedures that impact clinical study conduct. Conduct impact assessments of new regulations, guidances, and potential trends that may impact Clinical R&D.
  • Reviews and analyzes key Performance Indicator data and trends within organization as well as external assessments.
  • Analyzes risk and proposes remedial, corrective and /or preventive actions
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-43%

1 year growth

-45%

2 year growth

-18%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase II CENTAUR trial results bolster AMX0035's potential for ALS treatment.
  • Growing investment in rare disease research supports Amylyx's Wolfram syndrome efforts.
  • Regulatory support for fast-tracking treatments could expedite Amylyx's drug approvals.

What critics are saying

  • Phase III PHOENIX trial failure led to Relyvrio's market withdrawal, impacting revenue.
  • Workforce reduction by 70% may hinder Amylyx's operational and research capabilities.
  • Ongoing securities class action lawsuit poses financial and reputational risks.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases, specifically ALS and Alzheimer's.
  • AMX0035 is a unique combination therapy targeting nerve cell death prevention.
  • Amylyx engages in community awareness campaigns, enhancing its brand and mission alignment.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE